Johnson & Johnson Profit Margin 2006-2018 | JNJ

Current and historical gross margin, operating margin and net profit margin for Johnson & Johnson (JNJ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Johnson & Johnson net profit margin as of June 30, 2018 is 1.7%.
Johnson & Johnson Annual Profit Margin Summary
Johnson & Johnson Quarterly Profit Margin Summary
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $383.333B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $262.283B 15.35
Novartis AG (NVS) Switzerland $198.050B 16.99
Merck (MRK) United States $191.699B 16.93
AbbVie (ABBV) United States $139.707B 13.65
Novo Nordisk (NVO) Denmark $116.459B 18.62
Eli Lilly (LLY) United States $114.197B 21.14
Sanofi (SNY) France $109.227B 13.82
Bristol-Myers Squibb (BMY) United States $101.750B 18.42
GlaxoSmithKline (GSK) United Kingdom $99.941B 13.34
AstraZeneca (AZN) United Kingdom $95.440B 10.50